CSL Limited (ASX:CSL – Get Free Report) insider Megan Clark bought 132 shares of the company’s stock in a transaction dated Wednesday, February 19th. The stock was bought at an average cost of A$264.85 ($168.69) per share, with a total value of A$34,959.94 ($22,267.48).
CSL Stock Performance
The firm has a market cap of $77.43 billion, a PE ratio of 28.02, a P/E/G ratio of 1.29 and a beta of 0.32. The company has a debt-to-equity ratio of 64.46, a quick ratio of 1.68 and a current ratio of 1.86.
CSL Increases Dividend
The business also recently announced a Interim dividend, which will be paid on Tuesday, April 8th. Shareholders of record on Tuesday, April 8th will be paid a dividend of $2.073 per share. This represents a dividend yield of 0.81%. The ex-dividend date of this dividend is Sunday, March 9th. This is a boost from CSL’s previous Interim dividend of $1.83. CSL’s payout ratio is presently 50.38%.
About CSL
CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, and internationally. The company operates through CSL Behring, CSL Seqirus, and CSL Vifor segments. The CSL Behring segment offers plasma products, gene therapies, and recombinants.
See Also
- Five stocks we like better than CSL
- What Do S&P 500 Stocks Tell Investors About the Market?
- Unity Stock: Is a True Turnaround Finally Taking Shape?
- What is the Nikkei 225 index?
- DuPont’s Electronics Spinoff: The Start of Something Big
- Stock Analyst Ratings and Canadian Analyst Ratings
- The Trade Desk Crashes on Earnings, But Growth Catalysts Persist
Receive News & Ratings for CSL Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CSL and related companies with MarketBeat.com's FREE daily email newsletter.
